Healthcare & Life Sciences
Pulmotect
United States
series-c-plus
series-c-plus
Stage
1
Investors
About
Pulmotect develops immunotherapies to protect against respiratory infections by enhancing lung immune defenses.
Explore Pulmotect's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.